RP1 in Melanoma: When the Science Outlasted the CRLs

Article

The approval of vusolimogene oderparepvec (RP1) plus nivolumab for advanced melanoma following progression on anti–PD-1 therapy marks an important milestone for oncolytic immunotherapy—and the conclusion of an unusually complicated regulatory journey. RP1 is an engineered HSV-1 virus injected directly into tumors. Rather than targeting a specific oncogenic mutation, it is designed to make the tumor itself more immunogenic. Viral infection and fusogenic tumor-cell destruction release tumor antigens, while GM-CSF promotes immune activation. Nivolumab then blocks PD-1, allowing the newly generated or restored antitumor immune response to operate more effectively. The pivotal IGNYTE study provided a compelling signal. In 140 patients with melanoma that had progressed on anti–PD-1 therapy, RP1 plus nivolumab produced a32.9% objective response rate, including 15% complete responses, with a median duration of response of approximately 34 months. Importantly, responses were observed in uninjected as well as injected tumors, supporting the idea that RP1 can generate systemic immunity rather than simply destroy tumors locally. Yet RP1 received not one, but two FDA Complete Response Letters. The central issue was not whether responses had occurred. It was whether a single-arm study could establish that RP1 itself was responsible for enough of the benefit observed with the RP1-nivolumab combination. FDA questioned the absence of a randomized comparator, the heterogeneity of the study population and the ability to determine RP1's individual contribution. That makes the eventual approval particularly instructive. The biology did not suddenly change after the second CRL. The responses, complete responses, durability and regression of distant lesions were already evident. What evolved was the regulatory assessment of whether that body of evidence—considered alongside unmet need and ongoing randomized confirmation—was sufficient to support access to the therapy. The RP1 story therefore illustrates a growing challenge for precision oncology. Increasingly, therapies work not as isolated drugs but as interacting biological systems. RP1 does not simply release an immune checkpoint. It attempts to reconstruct the conditions necessary for checkpoint therapy to work: tumor destruction → antigen release → immune priming → systemic T-cell activation → PD-1 blockade. The ongoing randomized IGNYTE-3trial will now be critical in confirming the magnitude of that benefit. RP1's approval is therefore more than another melanoma treatment. It is a case study in how regulatory science must evaluate increasingly complex biological therapies—maintaining rigorous evidentiary standards while recognizing that the therapeutic mechanisms themselves are becoming more sophisticated.